Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Ysasaga

Ophthalmology Amarillo, TX Medical Doctor

NPI 1356310734 CMS profile 771899

7411 Wallace Blvd, Amarillo, TX 79106

Open in the dashboard

General payments

$15,259

144 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$73,463

6 holdings reported · through program year 2025

Research they led as principal investigator

$138,291 paid to institutions, not to them · program years 2022–2024

Through program year 2025, Jason Ysasaga of Amarillo, TX is reported in the CMS Open Payments database as having received $15,259 across 144 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $138,291 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $73,463 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,607 30
2024 General $3,587 34
2023 General $400 17
2022 General $6,648 24
2021 General $1,090 12
2020 General $786 11
2019 General $1,141 16
2024 Ownership $20,065 1
2023 Ownership $20,065 1
2022 Ownership $8,333 1
2021 Ownership $8,333 1
2020 Ownership $8,333 1
2019 Ownership $8,333 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Ysasaga
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Jason Ysasaga were reported at $1,607. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Jason Ysasaga Ophthalmology median Middle half National median
2019 $1,141 $258 $104–$655 $163
2020 $786 $126 $45–$321 $114
2021 $1,090 $205 $76–$534 $132
2022 $6,648 $266 $100–$678 $149
2023 $400 $308 $117–$745 $160
2024 $3,587 $340 $127–$846 $164
2025 $1,607 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genentech USA, Inc. $6,010 34 payments
  2. US Retina LLC $3,468 6 payments
  3. EyePoint Pharmaceuticals US, Inc. $2,086 5 payments
  4. Genentech, Inc. $778 2 payments
  5. Biogen, Inc. $545 14 payments
  6. Apellis Pharmaceuticals, Inc. $408 12 payments
  7. Alcon Vision LLC $384 13 payments
  8. Astellas Pharma US Inc $328 11 payments
  9. Regeneron Healthcare Solutions, Inc. $197 8 payments
  10. Novartis Pharmaceuticals Corporation $188 8 payments
  11. Other $868 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $5,700 3 payments
  2. Food and Beverage $4,197 129 payments
  3. Current or prospective ownership or investment interest $3,468 6 payments
  4. Travel and Lodging $1,691 3 payments
  5. Education $108 2 payments
  6. Entertainment $96 1 payment
Products named General payments · program years 2019–2025
  1. SUSVIMO $5,936 9 payments
  2. VABYSMO $4,886 21 payments
  3. EYP-1901 $2,073 4 payments
  4. Lucentis $328 10 payments
  5. Izervay $328 11 payments
  6. Syfovre $242 10 payments
  7. BYOOVIZ $215 8 payments
  8. EYLEA $197 8 payments
  9. BEOVU $154 6 payments
  10. Constellation $144 5 payments
  11. Other $1,479 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

425

Median for Ophthalmology: 891

Drug cost

$29,554

Median for Ophthalmology: $68,233

Branded share of claims

12.2%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Loteprednol Etabonate Generic 41 $8,433
Prolensa Bromfenac Sodium Brand 12 $4,766
Combigan Brimonidine Tartrate/Timolol Brand 15 $4,571
Prednisolone Acetate Generic 82 $3,383
Ketorolac Tromethamine Generic 109 $2,466
Bromfenac Sodium Generic 14 $1,961
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 11 $1,341
Brimonidine Tartrate Generic 20 $720
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 14 $659
Timolol Maleate Generic 30 $486

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$12,649,187

Of which drugs: $9,292,522

Medicare patients

2,463

Average age 78

Services billed

257,717

1,473 women, 990 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 34%
Ischemic heart disease 33%
Chronic kidney disease 25%
Atrial fibrillation 19%
Depression 19%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, faricimab-svoa, 0.1 mg J2777 Office 636 177,422 $4,847,098
Injection, avacincaptad pegol, 0.1 mg J2782 Office 325 45,920 $3,960,756
Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg Q5124 Office 76 1,073 $144,325
Injection, pegcetacoplan, intravitreal, 1 mg J2781 Office 39 856 $96,911
Injection, triamcinolone acetonide (xipere), 1 mg J3299 Office 17 1,044 $39,640
Injection, ranibizumab, 0.1 mg J2778 Office 13 103 $12,797
Injection, bevacizumab, 10 mg J9035 Office 13 27 $1,095
Injection, vancomycin hcl, 500 mg J3370 Office 13 14 $27
Injection, ceftazidime, per 500 mg J0713 Office 14 16 $21
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 14 14 $1

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SUSVIMO
  • Genentech USA, Inc. $705
$705 — —
VABYSMO
  • Genentech USA, Inc. $254
$254 — 177,422
BYOOVIZ
  • Biogen, Inc. $215
$215 — 1,073
Izervay
  • Astellas Pharma US Inc $137
$137 — 45,920
OZURDEX
  • AbbVie, Inc. $52
$52 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

144 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record